1-3 of 3
Keywords: etomoxir
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Articles

Fatty acid oxidation inhibitor etomoxir suppresses tumor progression and induces cell cycle arrest via PPARγ-mediated pathway in bladder cancer

Open Access
Songtao Cheng, Gang Wang, Yejinpeng Wang, Liwei Cai, Kaiyu Qian, Lingao Ju, Xuefeng Liu, Yu Xiao, Xinghuan Wang
Journal: Clinical Science
Clin Sci (Lond) (2019) 133 (15): 1745–1758.
https://doi.org/10.1042/CS20190587
Published: 07 August 2019
... increased in BCa compared with paracancerous tissues. Inhibition of fatty acid oxidation (FAO) with etomoxir caused lipid accumulation, decreased adenosine triphosphate (ATP) and nicotinamide adenine dinucleotide phosphate (NADPH) levels, suppressed BCa cell growth in vitro and in vivo , and reduced...
View articletitled, Fatty acid oxidation inhibitor etomoxir suppresses tumor progression and induces cell cycle arrest via PPARγ-mediated pathway in bladder cancer
Open the PDF for Fatty acid oxidation inhibitor etomoxir suppresses tumor progression and induces cell cycle arrest via PPARγ-mediated pathway in bladder cancer in another window
Includes: Supplementary data
Articles

A double-blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure: the ERGO (etomoxir for the recovery of glucose oxidation) study

Available to Purchase
Christian J. F. Holubarsch, Martin Rohrbach, Matthias Karrasch, Erich Boehm, Lech Polonski, Piotr Ponikowski, Siegfried Rhein
Journal: Clinical Science
Clin Sci (Lond) (2007) 113 (4): 205–212.
https://doi.org/10.1042/CS20060307
Published: 13 July 2007
...Christian J. F. Holubarsch; Martin Rohrbach; Matthias Karrasch; Erich Boehm; Lech Polonski; Piotr Ponikowski; Siegfried Rhein Etomoxir is an inhibitor of mitochondrial CPT1 (carnitine palmitoyltransferase 1) and thereby switches energy metabolism from fatty acids to glucose oxidation...
View articletitled, A double-blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure: the ERGO (etomoxir for the recovery of glucose oxidation) study
Open the PDF for A double-blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure: the ERGO (etomoxir for the recovery of glucose oxidation) study in another window
Articles

First clinical trial with etomoxir in patients with chronic congestive heart failure

Available to Purchase
Stephan SCHMIDT-SCHWEDA, Christian HOLUBARSCH
Journal: Clinical Science
Clin Sci (Lond) (2000) 99 (1): 27–35.
https://doi.org/10.1042/cs0990027
Published: 06 June 2000
... of a key protein in calcium cycling, i.e. the sarcoplasmic reticulum Ca 2+ -ATPase, and of the α-myosin heavy chain have been shown to be enhanced by treatment with etomoxir, a carnitine palmitoyltransferase inhibitor, in normal and pressure-overloaded rat myocardium. We therefore studied, for the first...
View articletitled, First clinical trial with etomoxir in patients with chronic congestive heart failure
Open the PDF for First clinical trial with etomoxir in patients with chronic congestive heart failure in another window